Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEST Extension
2018-000595-15Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adriforant in atopic dermatitis (AD) (2 arms), sponsored by Novartis. Primary endpoints: Frequency of adverse events at Week 32 and Frequency of adverse events at Week 116. Started Dec 2018; status: terminated.
02
Drugs
adriforant
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-000595-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000595-15.